Slovenian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
Journal of Medicinal Food 2012-Feb

Pharmacological review of Caralluma R.Br. with special reference to appetite suppression and anti-obesity.

Samo registrirani uporabniki lahko prevajajo članke
Prijava / prijava
Povezava se shrani v odložišče
Harish Chander Dutt
Surjeet Singh
Bharathi Avula
Ikhlas A Khan
Yashbir S Bedi

Ključne besede

Povzetek

Caralluma fimbriata extract has received Generally Recognized As Safe (GRAS) status for use as a nutraceutical to combat the most serious public health concern (i.e., obesity). More than 260 species grouped under the genus Caralluma (Family Apocynaceae) are distributed in tropical Asia and Mediterranean regions of the globe. Ethnobotanically, some species have been used as traditional and modern dietary ingredients to suppress appetite. Many species of Caralluma are commonly used as traditional medicine for the treatment of rheumatism, diabetes, leprosy, paralysis, and inflammation and have antimalarial, antitrypanosomal, anti-ulcer, antioxidant, antinociceptive, and antiproliferative activities. The genus is known for compounds like pregnane glycosides, flavonoid glycoside, flavones, magastigmane glycosides, pregnane steroids, steroidal glycosides, saturated and unsaturated hydrocarbons, aromatic and nonaromatic volatile compounds, and β-sitosterol. An extract of C. fimbriata (Slimaluna(®), Gencor Nutrients, Anaheim, CA, USA) is used as an anti-obesity agent and appetite suppressor. It is also seen that the pregnane glycosides isolated and identified from African Hoodia are reported as anti-obesity and appetite-suppressant compounds. On reviewing the studies undertaken on the chemistry, pharmacology, and therapeutic potential of Caralluma, it is concluded that the genus is also composed of pregnane glycosides as one of the major constituents. Availability of pregnane glycosides in Caralluma is an indication of the appetite-suppressant property of this genus. This coupled with the GRAS status of the extract of C. fimbriata has opened the possibility of developing an anti-obesity/appetite-suppressant product from other species of Caralluma. The main objective of this article is to review the studies undertaken on the plant in light of further research for anti-obesity drugs and nutraceuticals from species of Caralluma.

Pridružite se naši
facebook strani

Najbolj popolna baza zdravilnih zelišč, podprta z znanostjo

  • Deluje v 55 jezikih
  • Zeliščna zdravila, podprta z znanostjo
  • Prepoznavanje zelišč po sliki
  • Interaktivni GPS zemljevid - označite zelišča na lokaciji (kmalu)
  • Preberite znanstvene publikacije, povezane z vašim iskanjem
  • Iščite zdravilna zelišča po njihovih učinkih
  • Organizirajte svoje interese in bodite na tekočem z raziskavami novic, kliničnimi preskušanji in patenti

Vnesite simptom ali bolezen in preberite o zeliščih, ki bi lahko pomagala, vnesite zelišče in si oglejte bolezni in simptome, proti katerim se uporablja.
* Vse informacije temeljijo na objavljenih znanstvenih raziskavah

Google Play badgeApp Store badge